Interlude Biopharma registers Phase 3 trial of larazotide acetate in celiac disease
The study plans to enroll 414 participants and is expected to start in February 2027, with primary completion projected for August 2028. It is a randomized, double-blinded, placebo-controlled trial testing two doses of larazotide acetate to learn if it can help prevent signs and symptoms of celiac disease in well-controlled patients aged 12 and up.
Primary source
ClinicalTrials.gov registry record, November 18, 2026
Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease
Read the source: Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation